A recent $30 million agreement between Columbia and VIMRx Pharmaceuticals has contributed to a major expansion of Columbia???s Genome Center where investigators are on the forefront of the race to identify genes associated with cancer, Alzheimer???s disease, epilepsy, manic-depressive disorder, glaucoma, and other diseases.